학술논문
Association between SARS‐CoV‐2 viral kinetics and clinical score evolution in hospitalized patients
Document Type
Report
Author
Néant, Nadège; Lingas, Guillaume; Gaymard, Alexandre; Belhadi, Drifa; Hites, Maya; Staub, Thérèse; Greil, Richard; Paiva, Jose‐Artur; Poissy, Julien; Peiffer‐Smadja, Nathan; Costagliola, Dominique; Yazdanpanah, Yazdan; Bouscambert‐Duchamp, Maude; Gagneux‐Brunon, Amandine; Ader, Florence; Mentré, France; Wallet, Florent; Burdet, Charles; Guedj, Jérémie
Source
CPT: Pharmacometrics & Systems Pharmacology. December 2023, Vol. 12 Issue 12, p2027, 11 p.
Subject
Language
English
Abstract
Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) viral dynamics is associated with risk of death in hospitalized patients. WHAT QUESTION [...]
: The role of antiviral treatment in coronavirus disease 2019 hospitalized patients is controversial. To address this question, we analyzed simultaneously nasopharyngeal viral load and the National Early Warning Score 2 (NEWS‐2) using an effect compartment model to relate viral dynamics and the evolution of clinical severity. The model is applied to 664 hospitalized patients included in the DisCoVeRy trial (NCT04315948; EudraCT 2020‐000936‐23) randomly assigned to either standard of care (SoC) or SoC + remdesivir. Then we use the model to simulate the impact of antiviral treatments on the time to clinical improvement, defined by a NEWS‐2 score lower than 3 (in patients with NEWS‐2
: The role of antiviral treatment in coronavirus disease 2019 hospitalized patients is controversial. To address this question, we analyzed simultaneously nasopharyngeal viral load and the National Early Warning Score 2 (NEWS‐2) using an effect compartment model to relate viral dynamics and the evolution of clinical severity. The model is applied to 664 hospitalized patients included in the DisCoVeRy trial (NCT04315948; EudraCT 2020‐000936‐23) randomly assigned to either standard of care (SoC) or SoC + remdesivir. Then we use the model to simulate the impact of antiviral treatments on the time to clinical improvement, defined by a NEWS‐2 score lower than 3 (in patients with NEWS‐2